Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus HUMALOG MIX 50 50.
ADMELOG SOLOSTAR vs HUMALOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake, glycogen synthesis, and lipogenesis, and inhibit gluconeogenesis and ketogenesis.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Subcutaneous injection of 0.2 to 0.6 units/kg/day divided into 3 or more doses, with the preprandial dose based on blood glucose monitoring. Typical total daily dose is 0.5 units/kg/day. Administer within 15 minutes before or after a meal.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
Subcutaneous injection: terminal half-life approximately 1-2 hours, reflecting clearance from the injection site and systemic elimination. Clinical context: allows twice-daily dosing.
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Primarily via renal excretion of insulin degradation products; less than 1% excreted as unchanged insulin. No significant biliary or fecal elimination.
Category C
Category C
Insulin
Insulin